On September 11, 2026, an update was recorded for a clinical trial titled "A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study." The trial, registered as NCT02960022, is a Phase 2 study. Its current status is listed as active, not recruiting, meaning participant enrollment has closed while the study continues.
This trial involves leuprolide, an approved compound, in the context of prostate cancer research. The study population includes subjects who had previously participated in an enzalutamide clinical study. No results or outcome data are included in this update. The status reflects only the enrollment and operational phase of the trial as of the listed date.
This brief reports only the trial status and phase information as registered. It does not indicate efficacy, safety findings, or conclusions about leuprolide's performance in this study. Readers seeking further detail on trial design or eligibility can consult the official registry listing.
For additional background on this compound, readers can refer to the leuprolide overview page.